BACKGROUND: Inflammation persists in treated human immunodeficiency virus (HIV) infection and may contribute to an increased risk for non-AIDS-related pathologies. We investigated the correlation of cytokine responses with changes in CD4 T-cell levels and coinfection with hepatitis C virus (HCV) during highly active antiretroviral treatment (HAART). METHODS: A total of 383 participants in the Women's Interagency HIV Study (212 with HIV monoinfection, 56 with HCV monoinfection, and 115 with HIV/HCV coinfection) were studied. HIV-infected women had <1000 HIV RNA copies/mL, 99.7% had >200 CD4 T cells/μL; 98% were receiving HAART at baseline. Changes in CD4 T-cell count between baseline and 2-4 years later were calculated. Peripheral blood mononuclear cells (PBMCs) obtained at baseline were used to measure interleukin 1β (IL-1β), interleukin 6 (IL-6), interleukin 10 (IL-10), interleukin 12 (IL-12), and tumor necrosis factor α (TNF-α) responses to Toll-like receptor (TLR) 3 and TLR4 stimulation. RESULTS: Undetectable HIV RNA (<80 copies/mL) at baseline and secretion of IL-10 by PBMCs were positively associated with gains in CD4 T-cell counts at follow-up. Inflammatory cytokines (IL-1β, IL-6, IL-12, and TNF-α) were also produced in TLR-stimulated cultures, but only IL-10 was significantly associated with sustained increases in CD4 T-cell levels. This association was significant only in women with HIV monoinfection, indicating that HCV coinfection is an important factor limiting gains in CD4 T-cell counts, possibly by contributing to unbalanced persistent inflammation. CONCLUSIONS: Secreted IL-10 from PBMCs may balance the inflammatory environment of HIV, resulting in CD4 T-cell stability.
BACKGROUND:Inflammation persists in treated human immunodeficiency virus (HIV) infection and may contribute to an increased risk for non-AIDS-related pathologies. We investigated the correlation of cytokine responses with changes in CD4 T-cell levels and coinfection with hepatitis C virus (HCV) during highly active antiretroviral treatment (HAART). METHODS: A total of 383 participants in the Women's Interagency HIV Study (212 with HIV monoinfection, 56 with HCV monoinfection, and 115 with HIV/HCV coinfection) were studied. HIV-infectedwomen had <1000 HIV RNA copies/mL, 99.7% had >200 CD4 T cells/μL; 98% were receiving HAART at baseline. Changes in CD4 T-cell count between baseline and 2-4 years later were calculated. Peripheral blood mononuclear cells (PBMCs) obtained at baseline were used to measure interleukin 1β (IL-1β), interleukin 6 (IL-6), interleukin 10 (IL-10), interleukin 12 (IL-12), and tumor necrosis factor α (TNF-α) responses to Toll-like receptor (TLR) 3 and TLR4 stimulation. RESULTS: Undetectable HIV RNA (<80 copies/mL) at baseline and secretion of IL-10 by PBMCs were positively associated with gains in CD4 T-cell counts at follow-up. Inflammatory cytokines (IL-1β, IL-6, IL-12, and TNF-α) were also produced in TLR-stimulated cultures, but only IL-10 was significantly associated with sustained increases in CD4 T-cell levels. This association was significant only in women with HIV monoinfection, indicating that HCV coinfection is an important factor limiting gains in CD4 T-cell counts, possibly by contributing to unbalanced persistent inflammation. CONCLUSIONS: Secreted IL-10 from PBMCs may balance the inflammatory environment of HIV, resulting in CD4 T-cell stability.
Authors: Haitao Chu; Stephen J Gange; Xiuhong Li; Donald R Hoover; Chenglong Liu; Joan S Chmiel; Lisa P Jacobson Journal: Epidemiology Date: 2010-07 Impact factor: 4.822
Authors: Jennifer E Ho; Steven G Deeks; Frederick M Hecht; Yu Xie; Amanda Schnell; Jeffrey N Martin; Peter Ganz; Priscilla Y Hsue Journal: AIDS Date: 2010-07-31 Impact factor: 4.177
Authors: Frank J Palella; Stephen J Gange; Lorie Benning; Lisa Jacobson; Robert C Kaplan; Alan L Landay; Russell P Tracy; Richard Elion Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: G Greub; B Ledergerber; M Battegay; P Grob; L Perrin; H Furrer; P Burgisser; P Erb; K Boggian; J C Piffaretti; B Hirschel; P Janin; P Francioli; M Flepp; A Telenti Journal: Lancet Date: 2000-11-25 Impact factor: 79.321
Authors: Lars Peters; Amanda Mocroft; Vincent Soriano; Jürgen K Rockstroh; Marcelo Losso; Laure Valerio; Pauls Aldins; Peter Reiss; Bruno Ledergerber; Jens D Lundgren Journal: J Acquir Immune Defic Syndr Date: 2009-04-15 Impact factor: 3.731
Authors: K V Shmagel; L B Korolevskaya; E V Saidakova; N G Shmagel; V A Chereshnev; L Margolis; D Anthony; M Lederman Journal: Dokl Biol Sci Date: 2018-01-04
Authors: Elaine Cristina Cardoso; Nátalli Zanete Pereira; Gabrielle Eimi Mitsunari; Luanda Mara da Silva Oliveira; Rosa Maria S A Ruocco; Rossana Pulcineli Vieira Francisco; Marcelo Zugaib; Alberto José da Silva Duarte; Maria Notomi Sato Journal: PLoS One Date: 2013-06-27 Impact factor: 3.240
Authors: Pushpa Pandiyan; Souheil-Antoine Younes; Susan Pereira Ribeiro; Aarthi Talla; David McDonald; Natarajan Bhaskaran; Alan D Levine; Aaron Weinberg; Rafick P Sekaly Journal: Front Immunol Date: 2016-06-20 Impact factor: 7.561